As of May 31, 2026, the FDA reported 990+ adverse-event reports tied to compounded semaglutide and 730+ for other compounded GLP-1 products, citing risks from unapproved, non-sterile, or misbranded copycat products. The agency reiterated that compounded versions lack an FDA-approved-quality assurance.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.